A photo of Christopher Dandoy.

Christopher E. Dandoy, MD, MSc

  • Member, Division of Bone Marrow Transplantation and Immune Deficiency
  • Associate Professor, UC Department of Pediatrics



I have always enjoyed caring for patients and their families, and I appreciate the unique bond that forms during treatment. But as a physician, I’ve experienced the devastating impact bloodstream infections can have on children. On more than one occasion, my team has successfully cured a child’s cancer using stem cell transplant, only to lose them later to a bloodstream infection.

As a result, my research focuses on identifying, testing and implementing clinical strategies to help improve outcomes after stem cell transplantation for malignancy. My clinical work compliments my research focus since I am the physician lead for the autologous stem cell transplant program, caring for many patients with leukemia. I prioritize patient safety, quality improvement, and the prevention of bloodstream infections and cardiopulmonary complications, such as pulmonary hypertension.

Cincinnati Magazine recognized me as a Top Doctor in 2019 and 2020. Also, our Cancer and Blood Diseases Institute Quality Improvement and Patient Safety team won the Ohio Patient Safety Institute’s Dr. Frank Dono Best Practice Award.

I am co-editor of the book Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation, published in 2017 by Springer. I’ve served in several local and national leadership roles, including the co-physician lead for the Solutions for Patient Safety (SPS) Pediatric Hematology-Oncology Central Line-Associated Bloodstream Infection (CLABSI) reduction collaboration.

I serve as the vice chair of the American Society of Transplant and Cellular Therapy (ASTCT) Committee on Quality Outcomes. I am co-chair of the Center for International Blood and Marrow Transplant Research (CIBMTR) Infection and Immune Reconstitution Working Committee.

Additional Languages

Portuguese, Spanish


Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. Kapadia, M; Lehmann, L; Auletta, J; Beatty, L; Bhatt, N; Blacken, R; Demmel, K; Dodd, T; Desmond, C; Fitch, T; et al. Transplantation and cellular therapy. 2022; 28:233-241.

Abnormal Maximal and Submaximal Cardiopulmonary Exercise Capacity in Pediatric Stem Cell Transplant Recipients Despite Normal Standard Echocardiographic Parameters: A Pilot Study. Powell, AW; Urbina, EM; Madueme, P; Rotz, S; Chin, C; Taylor, MD; Mays, WA; Davies, SM; Lane, A; Berger, S; et al. Transplantation and cellular therapy. 2022; 28:263.e1-263.e5.

Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?. Jodele, S; Dandoy, CE; Sabulski, A; Koo, J; Lane, A; Myers, KC; Wallace, G; Chima, RS; Teusink-Cross, A; Hirsch, R; et al. Transplantation and cellular therapy. 2022.

US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Power-Hays, A; Dandoy, CE; Lorts, A; Perentesis, JP; Unaka, N; Ware, RE; McGann, PT. Pediatric Blood and Cancer. 2022.

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, AA; Jodele, S. Blood Advances. 2022; 6:1454-1463.

Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplantation Patients. Gardner, JC; Courter, JD; Dandoy, CE; Davies, SM; Teusink-Cross, A. Transplantation and cellular therapy. 2022; 28:167.e1-167.e5.

511 Defining Patient-Important Outcomes after Pediatric Hematopoietic Stem Cell Transplant. Fitch, TJ; Huber, J; Flesch, L; Jaglowski, S; Auletta, JJ; Lehmann, LE; Bhatt, NS; Mueller, M; Rotz, SR; Phelan, R; et al. Transplantation and cellular therapy. 2022; 28:s399-s400.

179 Weight Loss after Hematopoietic Stem Cell Transplantation for Malignancy. Fitch, TJ; Myers, KC; Davies, SM; Taggart, CB; Demmel, KM; Dandoy, CE. Transplantation and cellular therapy. 2022; 28:s148-s149.

Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients. Gardner, J; Courter, J; Dandoy, CE; Davies, SM; Teusink-Cross, A. Transplantation and cellular therapy. 2022; 28.

Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Singh, A; Dandoy, CE; Chen, M; Kim, S; Mulroney, CM; Kharfan-Dabaja, MA; Ganguly, S; Maziarz, RT; Kanakry, CG; Kanakry, JA; et al. Transplantation and cellular therapy. 2022; 28:48.e1-48.e10.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey